Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial Article

sustainable development goals

publication date

  • January 1, 2022

webpage

published in

keywords

  • apremilast
  • clinical trial
  • mild-to-moderate psoriasis
  • pruritus
  • quality-of-life
  • scalp

start page

  • 77

end page

  • 85

volume

  • 86

issue

  • 1